Breaking News

HBC, Catalent Enter Innovative Softgel Alliance

Partnership will leverage Catalent’s OptiGel DR technology to develop a delayed-release formulation of HBC’s OmeGo fish oil.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Hofseth BioCare ASA (HBC), a Norwegian biotech company that develops high-value ingredients and finished products, entered a global innovation partnership with Catalent to develop a delayed-release formulation of HBC’s OmeGo fish oil.   The partnership will leverage Catalent’s OptiGel DR technology to encapsulate OmeGo, HBC’s fish oil derived from sustainable, traceable, and fresh Norwegian Atlantic salmon. OptiGel DR technology enables an enteric release profile for softgel capsules without t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters